TUI1 TUI AG

TUI AG: Director Declaration

TUI AG (TUI)
TUI AG: Director Declaration

16-Jan-2020 / 12:01 CET/CEST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

16 January 2020

TUI AG

Director Declaration

TUI AG (the "Company") announces that it has been advised that Angelika Gifford, a member of the Company's Supervisory Board, has been appointed as the Vice President Central Europe of Facebook Inc., United States of America. At the same time, Ms Gifford resigned as a member of the Supervisory Board of ProSiebenSat.1 Media SE, Germany.

This announcement is made in accordance with Listing Rule 9.6.14.


 
ISIN: DE000TUAG000
Category Code: RDN
TIDM: TUI
LEI Code: 529900SL2WSPV293B552
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.: 40888
EQS News ID: 954755

 
End of Announcement EQS News Service

fncls.ssp?fn=show_t_gif&application_id=954755&application_name=news&site_id=research_pool
EN
16/01/2020

Underlying

TUI1TUI AG

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on TUI AG

Free Trial
TUI1 TUI AG

TUI AG: 2 directors

Two Directors at TUI AG bought 6,125 shares at between 7.910EUR and 7.930EUR. The significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...

12/11/25 December 11, 2025 1 EN
Si Yong Ng
  • Si Yong Ng
Free Trial
TUI1 TUI AG

TUI - Earnings Flash - FY 2024-25 Results - Lucror Analytics

TUI has reported solid FY 2024-25 numbers, with revenues growing c. 4% y-o-y and adjusted EBITDA rising c. 7%. This was driven by robust performances at Hotels & Resorts and Cruises, which offset poor results at Markets & Airlines. Cash-flow performance improved, helped by better earnings, a higher working-capital release and lower cash interest. Net leverage fell q-o-q and y-o-y to 0.6x.  We expect a solid FY 2025-26, backed by positive momentum in H1 for the Hotels & Resorts as well as Cru...

12/11/25 December 11, 2025 1 EN
Jayanth Kandalam ... (+4)
  • Jayanth Kandalam
  • Peter Low
  • Si Yong Ng
  • Tanvi Arora
Free Trial
TUI1 TUI AG
888 888 Holdings Pl...

Lucror Analytics - Morning Views Europe

In today's Morning Views publication we comment on developments of the following high yield issuers: evoke, Ineos, Ineos Quattro, Sammontana Italia, TUI, Fressnapf, David Lloyd Leisure

TUI1 TUI AG
888 888 HOLDINGS PLC
12/11/25 December 11, 2025 1 EN
Haidje Rustau ... (+5)
  • Haidje Rustau
  • Jayanth Kandalam
  • Peter Low
  • Si Yong Ng
  • Tanvi Arora
Free Trial
TUI1 TUI AG
BORR BORR DRILLING L...

Lucror Analytics - Morning Views Europe

In today's Morning Views publication we comment on developments of the following high yield issuers: United Group, MasOrange, Allwyn (formerly Sazka), Borr Drilling, PeopleCert, Polynt, TUI, David Lloyd Leisure, Asmodee, Paprec Group, Fressnapf

TUI1 TUI AG
BORR BORR DRILLING LTD
12/09/25 December 9, 2025 1 EN
Felix Fischer ... (+5)
  • Felix Fischer
  • Jayanth Kandalam
  • Peter Low
  • Si Yong Ng
  • Tanvi Arora
Free Trial
VK VALLOUREC SA
CCK Crown Holdings ... ... (+7)

Lucror Analytics - Morning Views Europe

In today's Morning Views publication we comment on developments of the following high yield issuers: Vallourec, Rekeep, Advanz Pharma, Kelvion (formerly Galapagos Holding), Recordati, Lecta, Clarios, Ardagh, Crown Holdings, TUI, David Lloyd Leisure, Centrient, Azelis

VK VALLOUREC SA
CCK CROWN HOLDINGS INC.
TUI1 TUI AG
REC RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A.
ARD ARDAGH GROUP S.A. CLASS A
LECTA LECTA
AZELIS AZELIS
11/13/25 November 13, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch